The Lewis Katz School of Medicine at Temple University, Philadelphia.
J Neuropsychiatry Clin Neurosci. 2019 Fall;31(4):386-391. doi: 10.1176/appi.neuropsych.18120383. Epub 2019 Jun 10.
Myasthenia gravis is a neuroimmunological disorder leading to skeletal muscle weakness. Common symptoms of the disease, such as anxiety, depression, and insomnia, can cause significant distress in patients. Unfortunately, selecting an appropriate medication for treatment of psychiatric comorbidities can prove to be challenging for providers given the unique pharmacologic constraints that myasthenia gravis presents. The authors present the following clinical vignette and accompanying discussion in an attempt to highlight the special considerations that must be taken into account when treating anxiety and insomnia in patients with myasthenia gravis, as well as to provide an overview of available medication options through the lens of existing constraints.
重症肌无力是一种神经免疫疾病,导致骨骼肌无力。该病的常见症状,如焦虑、抑郁和失眠,会给患者带来严重的困扰。不幸的是,由于重症肌无力的独特药理学限制,对于提供者来说,选择合适的药物来治疗精神共病可能具有挑战性。作者提出了以下临床病例和相关讨论,试图强调在治疗重症肌无力患者的焦虑和失眠时必须考虑的特殊注意事项,并通过现有的限制来概述可用的药物选择。